🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

198 results for “Novartis Ophthalmics Europe” Clear

  1. DZR123, DZR123, ENZALUTAMIDE

    Novartis Ophthalmics Europe

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  2. EGF816, EGF816, LEE011, LEE011

    Novartis Ophthalmics Europe

    Different types of advanced cancer

    phase 2 small molecule active

    1 trial

  3. EGF816, INC280, EGF816, GEFITINIB, INC280, EGF816

    Novartis Ophthalmics Europe

    cMET-dependent malignancies

    phase 2 small molecule active

    1 trial

  4. ENTECAVIR , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -, VAY736

    Novartis Ophthalmics Europe

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial

  5. ETOPOSIDE, YTB323, CYTARABINE, CYCLOPHOSPHAMIDE MONOHYDRATE, BENDAMUSTINE HYDROCHLORIDE, FLUDARABINE PHOSPHATE, IBRUTINIB, TOCILIZUMAB

    Novartis Ophthalmics Europe

    High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  6. FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, TOCILIZUMAB, YTB323

    Novartis Ophthalmics Europe

    Systemic Lupus Erythematosus., Lupus Nephritis

    phase 2 small molecule active

    1 trial

  7. FLUDARABINE PHOSPHATE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, BENDAMUSTINE, PHE885

    Novartis Ophthalmics Europe

    Adult patients with relapsed and refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  8. FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE, TOCILIZUMAB

    Novartis Ophthalmics Europe

    Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement

    phase 2 small molecule active

    1 trial

  9. FWY003, FWY003, Placebo to FWY003, FWY003

    Novartis Ophthalmics Europe

    Geographic atrophy secondary to age-related macular degeneration

    phase 2 small molecule active

    1 trial

  10. GHZ339, -, Placebo to GHZ339, -, PIMECROLIMUS , TACROLIMUS , -

    Novartis Ophthalmics Europe

    Moderate to severe atopic dermatitis

    phase 2 small molecule active

    1 trial

  11. GIA632, Placebo to GIA632 150 mg/mL solution for injection

    Novartis Ophthalmics Europe

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  12. GXV813, GXV813, Placebo 0 mg Hard gelatin capsule

    Novartis Ophthalmics Europe

    Schizophrenia

    phase 2 small molecule active

    1 trial

  13. HYDROCORTISONE, PREDNISOLONE ACETATE PH. EUR., ASCIMINIB HYDROCHLORIDE, CYTARABINE, DEXAMETHASONE, BLINATUMOMAB, Asciminib, METHOTREXATE, DBL methotrexate injection, VINCRISTINE SULFATE, DEXAMETHASONE SODIUM PHOSPHATE

    Novartis Ophthalmics Europe

    relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

    phase 2 small molecule active

    1 trial

  14. IDARUBICIN, FLUDARABINE, CYTARABINE, DAUNORUBICIN, MITOXANTRONE, ETOPOSIDE, PKC412

    Novartis Ophthalmics Europe

    untreated FLT3-mutated Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  15. IPTACOPAN, Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023)

    Novartis Ophthalmics Europe

    active antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis

    phase 2 small molecule active

    1 trial

  16. JDQ443

    Novartis Ophthalmics Europe

    Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

    phase 2 small molecule active

    1 trial

  17. LEE011, LEE011, LTT462, LXH254, LXH254, TMT212, LXH254, LTT462, LXH254

    Novartis Ophthalmics Europe

    Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

    phase 2 small molecule active

    1 trial

  18. LEE011, TMT212, Mekinist 2 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, TMT212, JDQ443, CETUXIMAB

    Novartis Ophthalmics Europe

    Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors

    phase 2 small molecule active

    1 trial

  19. LEUPRORELIN ACETATE, FULVESTRANT, ECI830, GOSERELIN, LEUPRORELIN ACETATE, GOSERELIN, RIBOCICLIB, ECI830, ECI830

    Novartis Ophthalmics Europe

    Advanced solid tumors, Advanced HR+/HER2- breast cancer

    phase 2 small molecule active

    1 trial

  20. LEUPRORELIN ACETATE, LETROZOLE, GVV858, LEUPRORELIN ACETATE, FULVESTRANT, GVV858, GOSERELIN, GOSERELIN

    Novartis Ophthalmics Europe

    Advanced HR+/HER- breast cancer

    phase 2 small molecule active

    1 trial

  21. LISINOPRIL , XXB750, AZILSARTAN MEDOXOMIL , CANDESARTAN , BENAZEPRIL , TRANDOLAPRIL , FOSINOPRIL , PERINDOPRIL , MOEXIPRIL , QUINAPRIL , CAPTOPRIL , EPROSARTAN , RAMIPRIL , IRBESARTAN , VALSARTAN AND SACUBITRIL , ZOFENOPRIL , CILAZAPRIL , DELAPRIL , OLMESARTAN MEDOXOMIL , IMIDAPRIL , 0 mg/1 mL Placebo to XXB750 150 mg/1 mL concentrate for solution for injection, ENALAPRIL , TELMISARTAN , VALSARTAN , LOSARTAN

    Novartis Ophthalmics Europe

    Heart Failure

    phase 2 small molecule active

    1 trial

  22. LNA043

    Novartis Ophthalmics Europe

    Osteoarthritis

    phase 2 small molecule active

    1 trial

  23. LOU064, -, -, Placebo to LOU064 Film-coated tablet

    Novartis Ophthalmics Europe

    Chronic Inducible urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  24. LTP001, Placebo to LTP001 1mg and 5mg hard gelatin capsules, LTP001

    Novartis Ophthalmics Europe

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources